Delving into the Latest Updates on IPF PharmaCeuticals GmbH with Synapse

概览

疾病领域	数量

感染	1

排名前五的药物类型	数量

血液提取物	1

排名前五的靶点	数量

LEAP2	1

关联

2

项与 IPF PharmaCeuticals GmbH 相关的药物

Liver-expressed antimicrobial peptide 2

靶点

LEAP2

作用机制

LEAP2 modulators

在研机构

IPF PharmaCeuticals GmbH

原研机构

IPF PharmaCeuticals GmbH

在研适应症

细菌感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Hemoparatide

靶点

PTH1R

作用机制

PTH1R激动剂

在研机构-

原研机构

PHARIS Biotec GmbH

在研适应症-

非在研适应症

甲状旁腺功能减退症 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 IPF PharmaCeuticals GmbH 相关的临床结果

登录后查看更多信息

0 项与 IPF PharmaCeuticals GmbH 相关的专利（医药）

登录后查看更多信息

31

项与 IPF PharmaCeuticals GmbH 相关的文献（医药）

2011-11-01·The Veterinary Journal2区 · 农林科学

Long-term effects of intermittent equine parathyroid hormone fragment (ePTH-1-37) administration on bone metabolism in healthy horses

2区 · 农林科学

Article

作者: Vervuert, Ingrid ; Parvizi, Nahid ; Martin-Rosset, William ; Weisrock, Katharina U ; Winkelsett, Sarah ; Forssmann, Wolf-Georg ; Coenen, Manfred

Intermittent administration of parathyroid hormone (PTH) is an anabolic therapy for osteoporotic conditions in humans. This study evaluated the effects of equine PTH fragment (ePTH-1-37) administration on bone metabolism in 12 healthy horses. Six horses each were treated once daily for 120days with subcutaneous injections of 0.5μg/kg ePTH-1-37 or placebo. Blood was collected to determine ionized calcium (Ca(++)), total Ca (Ca(T)), inorganic phosphorus, serum equine osteocalcin (eOC), carboxy-terminal telopeptide of type I collagen (ICTP), bone-specific alkaline phosphatase, and carboxy-terminal cross-linked telopeptide of type I collagen. Bone mineral density (BMD) was determined with dual X-ray absorptiometry of the metacarpus and calcaneus. Significantly higher blood Ca(++) and plasma Ca(T) concentrations were measured 5h after ePTH-1-37 administration compared to placebo. Higher serum eOC concentrations were found for ePTH-1-37 treatment at days 90 (P<0.05) and 120 (P=0.05). Significantly higher serum ICTP levels were observed with ePTH-1-37 treatment at days 60 and 90. For both study groups, BMD increased significantly in the calcaneus. Long-term use of ePTH-1-37 seemed to have no negative effects on bone metabolism in healthy horses. The absence of undesirable side effects is the premise to ensure safety for further clinical investigations in horses with increased bone resorption processes.

2008-03-01·The Journal of Sexual Medicine2区 · 医学

Expression and Distribution of Cyclic GMP-Dependent Protein Kinase-1 Isoforms in Human Penile Erectile Tissue

2区 · 医学

Article

作者: Richter, Karin ; Wolf, Gerald ; Sohn, Michael ; Langnaese, Kristina ; Stief, Christian ; Sigl, Katja ; Hedlund, Petter ; Jonas, Udo ; Imkamp, Florian ; Waldkirch, Eginhard ; Uckert, Stefan

ABSTRACTIntroductionBesides the bioavailability of nitric oxide (NO), downstream guanine monophosphate (cGMP) effector proteins are also considered to play a significant role in penile vascular disease. In animal studies, a downregulation of the cGMP-dependent protein kinase-1 (cGKI) α isoform has been linked to erectile dysfunction and diabetes mellitus. So far, the expression of cGKI α and β isoforms has not been evaluated in human penile erectile tissue.AimTo evaluate the expression of cGKI α and β isoforms in relation to smooth muscle α-actin, cGMP, and endothelial NO synthase (eNOS) in human cavernous arteries (HCAs) and human corpus cavernosum (HCC).MethodsCryostat sections of HCA and HCC were incubated with primary antibodies directed against α-actin, cGMP, eNOS, cGKI, cGKI α, and cGKI β. Visualization of double-labeled immunofluorescent stainings was achieved by laser microscopy. Western blot analysis was performed in order to confirm the expression of cGKI isoforms.Main Outcome MeasuresExpression of cGKI α and β isoforms in relation to smooth muscle α-actin, cGMP, and eNOS in human penile erectile tissue.ResultsImmunoreactivities specific for cGKI, cGKI α, and cGKI β were observed within the smooth musculature and the endothelium of cavernous arteries and sinusoids. Double stainings revealed the colocalization of alpha-actin, cGMP, eNOS, and cGKI isoforms. The expression of cGKI isoforms was confirmed by Western blot analysis.ConclusionsOur results demonstrate, for the first time, the expression of both cGKI α and β isoforms in the smooth musculature of HCA and HCC. Corresponding to recent findings from animal studies, the presence of cGKI α and β provides further evidence for a significant role of these enzymes in the control of smooth muscle function in human penile erectile tissue.

2008-02-25·European journal of medical research

N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.

Article

作者: Adermann, Knut ; Meyer, Markus ; Maronde, Erik ; John, Harald ; Forssmann, Wolf-Georg

Since its discovery glucagon-like peptide-1 (GLP-1) is investigated as a treatment for type II diabetes based on its major function as insulin secretagogue. A therapeutic use is, however, limited by its short biological half-life in the range of minutes, predominantly caused via degradation catalyzed by dipeptidyl peptidase IV (DPP-IV). Therefore, we aimed to design a GLP-1 analogue exhibiting resistance against DPP-IV-catalyzed inactivation while retaining its biological activity. By means of matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) we have studied the stability of the N-terminally blocked new analogue Ac-GLP-1-(7-34)-amide against DPP-IV and compared it with both unblocked GLP-1-(7-34)-amide and the major naturally occurring form GLP-1-(7-36)-amide. GLP-1-(7-36)-amide and the C-terminally two amino acid residues shorter GLP-1-(7-34)-amide rapidly generated peptide fragments truncated by the N-terminal dipeptide. In contrast, the N-terminal blocked Ac-GLP-1-(7-34)-amide was not degraded in the presence of DPP-IV over a period of at least two hours. Ac-GLP-1-(7-34)-amide induced a concentration-dependent increase of intracellular cAMP production and insulin release from rat insulinoma RIN-m5F cells to an extent comparable to that found for the N-terminally unblocked peptides GLP-1-(7-34)-amide and GLP-1-(7-36)-amide. Ac-GLP-1-(7-34)-amide may thus have the potential to act as a new long-acting GLP-1 analogue with significant resistance against DPP-IV and retained biological activity in vitro. Further research is required to investigate whether Ac-GLP-1-(7-34)-amide also exhibits its characteristics in animal models and humans.

100 项与 IPF PharmaCeuticals GmbH 相关的药物交易

登录后查看更多信息

100 项与 IPF PharmaCeuticals GmbH 相关的转化医学

登录后查看更多信息